Business
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued
About this update from Biomerica, Inc.
[{"type":"text","content":"IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that offers a revolutionary new way to treat patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application #16/385,322 contains numerous claims that broadly cover the method that enables physicians to identify patient specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed may alleviate or improve an individual's IBS symptoms, such as constipation, diarrhea, bloating, severe cramping, pain and indigestion.\n The InFoods® diagnostic guided IBS therapy is in clinical studies at Mayo Clinic, University of Texas Health Science Center at Houston, Houston Methodist (part of Texas Medical Center, the largest medical complex in the world), Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and at the University of Michigan. Since the InFoods® IBS product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. Several members of the ROME Foundation have been working with the company to design and set up these trials. Further the company expects the clinical trial sites will be active users of the product upon clearance by the FDA. It is estimated that over 45 million Americans suffer from IBS and the symptoms are often triggered by consumption of specific foods (which are unique in each sufferer). The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair patient well-being and a person’s ability to function both at home and in the workplace. A billable CPT code already exists that can be used by both clinical labs and physicians' offices upon clearance by the FDA. Biomerica has several additional U.S. and international patent applications in prosecution that cover other claims pertaining to the InFoods® IBS product. Further, Biomerica has filed patents, and is developing diagnostic guided therapies for other diseases utilizing the InFoods® technology platform, which include: functional dyspepsia, Crohn’s dise...